Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
about
Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli CellsPI3K and cancer: lessons, challenges and opportunitiesThe Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.Genetically engineered mouse models of PI3K signaling in breast cancer.Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110αPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.Capillary Isoelectric Focusing of Akt Isoforms Identifies Highly Dynamic Phosphorylation in Neuronal Cells and Brain TissuePI3K pathway dependencies in endometrioid endometrial cancer cell lines.Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN lossG protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness.Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.PI3King the right partner: unique interactions and signaling by p110β.Molecules in medicine mini-review: isoforms of PI3K in biology and disease.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers.Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury.Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
P2860
Q28546072-177A53E6-6AD8-4426-A537-BB547E10F6FCQ30080017-38EC0EEE-82E3-4F75-9491-34C43E72B953Q31070331-62D5E3D6-4233-4713-AC51-573885D74222Q33674643-C3B685D2-DE59-4C88-85A2-1DBC4EFC6B55Q34332175-39E69CE6-E07B-47C6-B2BD-DB1AFBFC3E9FQ34590266-5C0E0F2F-6B50-41DF-99E0-F62759B38D28Q35260766-466A5D33-A8D2-456C-8F80-89901914E2DDQ35746524-C6F58CE1-70A0-46CD-8995-5BF0C7DB5D4FQ36086507-38429991-0D83-40C8-9B3D-E3BAAE7CD32CQ36139665-486B904C-2129-4551-959D-E98882CFC51EQ36876219-10781E46-1AC2-4179-BC92-11A79D709E3FQ36980561-9FA5FDBB-F078-4E41-93B5-36AFC66DEE9EQ37064604-43F72290-7230-4F96-9250-80A3F4332C72Q37309754-56B28D41-8454-4B8B-9E97-034CAD4F76A3Q37691538-8AD74109-4532-437F-9488-CB7BD439992DQ38081658-699D4E47-0533-4760-81BD-B3D6A7E93B6EQ38265574-3EF4E528-3786-4209-8F91-3655578B74BBQ38542387-C6A9A6EA-0E90-451C-9D63-7EF5CC86CE27Q38666875-B7CB6D96-E294-438F-BD96-8EA429A9F583Q38699761-9CA07339-6EA3-4404-8258-1AFA8F778B6FQ38852858-F334EE21-29BC-4EA6-A86C-19B25CF0CD50Q39036639-F28E6B25-AB50-4FBE-8208-D56F525514A7Q40082014-25B26664-B05B-4296-AFC8-392AC2DF6200Q40970798-72424EA9-467B-45F1-B5E2-EF4A648AD59CQ42030378-F264529F-8B57-49F0-855E-6FCB5B292079Q47111476-1A30B1EF-F314-4CD2-BCF7-400F7F038979Q47160630-582A8A72-58D5-4EEC-9546-40CDA3B81277Q50195654-8A97955C-53A6-4544-86E6-9CCE61E1BC81Q51308924-B99F1169-B614-4A05-ADD5-BDEA539A6B8EQ55274845-493E3AC9-8C0A-481F-96D7-FACEAD6084A6
P2860
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Both p110α and p110β isoforms ...... of the PTEN tumour suppressor.
@en
type
label
Both p110α and p110β isoforms ...... of the PTEN tumour suppressor.
@en
prefLabel
Both p110α and p110β isoforms ...... of the PTEN tumour suppressor.
@en
P2093
P2860
P356
P1433
P1476
Both p110α and p110β isoforms ...... of the PTEN tumour suppressor.
@en
P2093
Bart Vanhaesebroeck
Inma M Berenjeno
Stewart Fleming
Wayne Pearce
P2860
P304
P356
10.1042/BJ20111741
P407
P577
2012-02-01T00:00:00Z